We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
SQZ Biotechnologies today announced the appointments of Bernard Coulie, M.D., Ph.D., and Patrick Vink, M.D., to its board of directors, adding global commercial and clinical development expertise.
SQZ Biotechnologies has raised $72 million. The series C round sets the Roche-partnered MIT spinout to advance cell therapy treatments of solid tumors and autoimmune diseases toward the clinic.